1 | O-15 Water | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 6 6 |
2 | Oats | 1件: Oat Oat | - | - | - | 1件: 97 97 |
3 | OAV101 | - | - | - | - | 1件: 3 3 |
4 | Obatoclax | 1件: Obatoclax Obatoclax | - | - | - | 1件: 60 60 |
5 | Obatoclax mesylate (GX15-070MS) | 1件: Obatoclax Obatoclax | - | - | - | 1件: 60 60 |
6 | Obefazimod | - | - | - | - | 1件: 97 97 |
7 | Obeticholic Acid | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 3件: 93 93, 265, 296 |
8 | Obeticholic Acid (OCA) | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
9 | Obeticholic Acid 10 MG | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
10 | Obeticholic Acid 5 MG | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
11 | Obeticholic Acid Tablets | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
12 | Obexelimab | 1件: Obexelimab Obexelimab | 1件: D11496
D11496
| 1件: CD19 CD19 💬 | 5件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Hematopoietic cell lineage, PI3K-Akt signaling pathway, Primary immunodeficiency 💬 | 1件: 300 300 |
13 | OBI-1 | - | - | - | - | 1件: 288 288 |
14 | Obinutuzumab | 1件: Obinutuzumab Obinutuzumab | 1件: D09321
D09321
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 4件: 43 43, 44, 49, 222 |
15 | Obinutuzumab administration | 1件: Obinutuzumab Obinutuzumab | 1件: D09321
D09321
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 49 49 |
16 | OBINUTUZUMAB/ GA101 | 1件: Obinutuzumab Obinutuzumab | 1件: D09321
D09321
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 |
17 | Obitunuzumab | - | - | - | - | 1件: 222 222 |
18 | OBIZUR | 1件: Susoctocog alfa Susoctocog alfa | 1件: D10831
D10831
| - | - | 1件: 288 288 |
19 | Observational study | - | - | - | - | 2件: 46 46, 271 |
20 | Observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi | 4件: Epoprostenol Epoprostenol, Iloprost, Macitentan, Selexipag | 4件: D00106
D00106
,
D02721
,
D09994
,
D10135
| 3件: EDNRA EDNRA, EDNRB, PTGIR 💬 | 10件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Platelet activation, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
21 | Obyoctocog alfa | - | - | - | - | 1件: 288 288 |
22 | OC oral solution treatment A | - | - | - | - | 1件: 6 6 |
23 | OC oral solution treatment B | - | - | - | - | 1件: 6 6 |
24 | OC oral solution treatment C | - | - | - | - | 1件: 6 6 |
25 | OC oral solution treatment D | - | - | - | - | 1件: 6 6 |
26 | OC000459 | - | - | - | - | 1件: 98 98 |
27 | OCA | - | - | - | - | 2件: 94 94, 296 |
28 | OCA (INT-747) | - | - | - | - | 1件: 93 93 |
29 | OCA 0.1 mg | - | - | - | - | 1件: 296 296 |
30 | OCA 0.1mg | - | - | - | - | 1件: 296 296 |
31 | OCA 1,5 mg | - | - | - | - | 1件: 94 94 |
32 | OCA 1.5mg | - | - | - | - | 1件: 296 296 |
33 | OCA 5 mg | - | - | - | - | 1件: 94 94 |
34 | OCA 5mg | - | - | - | - | 1件: 296 296 |
35 | OCA, INT-747 | - | - | - | - | 1件: 93 93 |
36 | Ocaliva | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 2件: 93 93, 296 |
37 | Ocaliva 10mg | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
38 | Ocaliva 5mg | 1件: Obeticholic acid Obeticholic acid | 1件: D09360
D09360
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 |
39 | OCH-NCNP1 | - | - | - | - | 1件: 13 13 |
40 | Oclelizumab | - | - | - | - | 1件: 13 13 |
41 | OCR | - | - | - | - | 1件: 13 13 |
42 | OCRELIZUMAB | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 3件: 13 13, 46, 49 |
43 | Ocrelizumab (CinnaGen, Iran) | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
44 | Ocrelizumab (Roche, Switzerland) | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
45 | Ocrelizumab / rhuMAb 2H7 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
46 | Ocrelizumab 300 mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
47 | Ocrelizumab 300mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
48 | Ocrelizumab 300mg /10ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
49 | Ocrelizumab 300mg/10 ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
50 | Ocrelizumab 300mg/10ml | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
51 | Ocrelizumab 500mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
52 | Ocrelizumab 600 mg | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
53 | Ocrelizumab at home | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
54 | Ocrelizumab Dose 1 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
55 | Ocrelizumab Dose 2 and Dose 3 | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
56 | Ocrelizumab IV | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
57 | Ocrelizumab SC | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
58 | Ocrelizumabu 200mg | - | - | - | - | 1件: 46 46 |
59 | Ocrelizumabu 50mg | - | - | - | - | 1件: 46 46 |
60 | OCREVUS | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
61 | Ocrevus 300 mg, solution à diluer pour perfusion | 1件: Ocrelizumab Ocrelizumab | 1件: D05218
D05218
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
62 | OCRH | - | - | - | - | 2件: 75 75, 232 |
63 | Ocrrelizumab 300 mg | - | - | - | - | 1件: 13 13 |
64 | OCTA-C1-INH | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
65 | OctaAlpha1 | - | - | - | - | 1件: 231 231 |
66 | Octagam | - | - | - | - | 2件: 13 13, 65 |
67 | Octagam 10% | - | - | - | - | 3件: 50 50, 63, 65 |
68 | Octagam 5% | - | - | - | - | 2件: 13 13, 65 |
69 | Octagam 50 mg/ml | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 13 13 |
70 | OCTAGAM 50 mg/ml oldatos infúzió | - | - | - | - | 1件: 65 65 |
71 | Octagam® 10% | - | - | - | - | 1件: 63 63 |
72 | Octanate | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
73 | OCTANATE 100 UI/ml, poudre et solvant pour solution injectable | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
74 | OCTANATE 50 UI/ml, poudre et solvant pour solution injectable | 1件: Beroctocog alfa Beroctocog alfa | - | - | - | 1件: 288 288 |
75 | Octanorm | - | - | - | - | 2件: 50 50, 65 |
76 | Octanorm 16.5% | - | - | - | - | 2件: 50 50, 65 |
77 | Octaplas | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 |
78 | Octaplas infusion | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 |
79 | Octaplas SD | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 |
80 | OctaplasLG® | - | - | - | - | 1件: 64 64 |
81 | Octaplas®LG | 1件: Plasma protein fraction (human) Plasma protein fraction (human) | - | - | - | 1件: 64 64 |
82 | Octeotride | - | - | - | - | 1件: 67 67 |
83 | OCTOCOG ALFA | 1件: Antihemophilic factor, human recombinant Antihemophilic factor, human recombinant | - | - | - | 1件: 288 288 |
84 | Octostim | - | - | - | - | 2件: 64 64, 288 |
85 | Octreotide | 1件: Octreotide Octreotide | 1件: D00442
D00442
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 7件: 67 67, 75, 84, 85, 89, 193, 227 |
86 | Octreotide a azione pronta 0,1 mg | 1件: Octreotide Octreotide | 1件: D00442
D00442
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 |
87 | OCTREOTIDE ACETATE | 2件: Acetate Acetate, Octreotide | 1件: D00442
D00442
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 |
88 | OCTREOTIDE ACETATO | 1件: Octreotide Octreotide | 1件: D00442
D00442
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 227 227 |
89 | Octreotide LAR | 1件: Octreotide Octreotide | 1件: D00442
D00442
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 2件: 67 67, 227 |
90 | Octreotide LAR / Sandostatin LAR (LAR=long acting release) | 1件: Octreotide Octreotide | 1件: D00442
D00442
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 |
91 | Octreotide-LAR | 1件: Octreotide Octreotide | 1件: D00442
D00442
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 67 67 |
92 | OCU400 High Dose | - | - | - | - | 1件: 90 90 |
93 | OCU400 Low Dose | - | - | - | - | 1件: 90 90 |
94 | OCU400 Mid Dose | - | - | - | - | 1件: 90 90 |
95 | Ocufolin | - | - | - | - | 1件: 13 13 |
96 | Odevixibat | 1件: Odevixibat Odevixibat | 1件: D11716
D11716
| 1件: SLC10A2 SLC10A2 💬 | 1件: Bile secretion Bile secretion 💬 | 3件: 296 296, 297, 338 |
97 | Odiparcil | 1件: Odiparcil Odiparcil | - | - | - | 1件: 19 19 |
98 | ODM-101 | - | - | - | - | 1件: 6 6 |
99 | ODM-101 105mg Carbidopa | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
100 | ODM-101 65mg Carbidopa | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
101 | ODM-104 | - | - | - | - | 1件: 6 6 |
102 | ODM-109 | - | - | - | - | 1件: 2 2 |
103 | ODM-109 capsule 1 mg | - | - | - | - | 1件: 2 2 |
104 | ODSH at 0.125 mg/kg/h | - | - | - | - | 1件: 210 210 |
105 | ODSH at 0.250 mg/kg/h | - | - | - | - | 1件: 210 210 |
106 | ODSH at 0.375 mg/kg/h | - | - | - | - | 1件: 210 210 |
107 | Oestrogen | - | - | - | - | 1件: 78 78 |
108 | OFATUMUMAB | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 3件: 13 13, 35, 46 |
109 | Ofatumumab 100 | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
110 | Ofatumumab 300 | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
111 | Ofatumumab 30mg | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
112 | Ofatumumab 3mg | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
113 | Ofatumumab 60mg | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
114 | Ofatumumab 700 | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
115 | Ofatumumab subcutaneous injection | 1件: Ofatumumab Ofatumumab | 1件: D09314
D09314
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 13 13 |
116 | Ofev | 1件: Nintedanib Nintedanib | 1件: D10481
D10481
| 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 5件: 51 51, 85, 89, 227, 228 |
117 | Ofev 100 mg capsule | 1件: Nintedanib Nintedanib | 1件: D10481
D10481
| 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 |
118 | Ofev 150 mg capsule | 1件: Nintedanib Nintedanib | 1件: D10481
D10481
| 8件: FGFR1 FGFR1, FGFR2, FGFR3, FLT1, FLT4, KDR, PDGFRA, PDGFRB 💬 | 34件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Choline metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, Gap junction, Gastric cancer, Glioma, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, PI3K-Akt signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Thermogenesis, Transcriptional misregulation in cancer, VEGF signaling pathway 💬 | 1件: 85 85 |
119 | OFEV® | - | - | - | - | 1件: 85 85 |
120 | OGT 918 | - | - | - | - | 2件: 19 19, 299 |
121 | OGT918 | - | - | - | - | 1件: 19 19 |
122 | OGT923 | - | - | - | - | 1件: 19 19 |
123 | OK432 | - | - | - | - | 1件: 278 278 |
124 | Okrido | - | - | - | - | 1件: 3 3 |
125 | Okrido 6mg/mL oral solution | - | - | - | - | 1件: 3 3 |
126 | Oksikodoni | - | - | - | - | 1件: 70 70 |
127 | OL adalimumab 40 mg | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 96 96 |
128 | OLANZAPINE | 1件: Olanzapine Olanzapine | 1件: D00454
D00454
| 11件: ADRA1A ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2B, HTR2C, HTR6 💬 | 16件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Salivary secretion, Serotonergic synapse, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 2件: 2 2, 8 |
129 | Olaparib | 1件: Olaparib Olaparib | 1件: D09730
D09730
| 2件: PARP1 PARP1, PARP2 💬 | 5件: Apoptosis Apoptosis, Base excision repair, Diabetic cardiomyopathy, NF-kappa B signaling pathway, Necroptosis 💬 | 2件: 86 86, 285 |
130 | OLE BSA Adalimumab +/- MTX | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 |
131 | OLE FD Adalimumab +/- MTX | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 |
132 | Oleic Acid | 1件: Oleic Acid Oleic Acid | 1件: D02315
D02315
| - | - | 2件: 13 13, 299 |
133 | Oleic acid supplementation | 1件: Oleic Acid Oleic Acid | 1件: D02315
D02315
| - | - | 1件: 299 299 |
134 | OLENASUFLIGENE RELDUPARVOVEC | 1件: Olenasufligene relduparvovec Olenasufligene relduparvovec | - | - | - | 1件: 19 19 |
135 | Oleogel-S10 | 1件: Birch bark extract Birch bark extract | - | - | - | 1件: 36 36 |
136 | Oleovit D3 14.400 IU/ml oral drops, solution | - | - | - | - | 1件: 13 13 |
137 | Olesoxime | 1件: Olesoxime Olesoxime | 1件: D11213
D11213
| - | - | 3件: 2 2, 3, 13 |
138 | Olesoxime (TRO19622) | 1件: Olesoxime Olesoxime | 1件: D11213
D11213
| - | - | 1件: 13 13 |
139 | Oligofructose enriched inulin | 1件: Inulin Inulin | 1件: D00171
D00171
| - | - | 1件: 96 96 |
140 | OligoG | - | - | - | - | 1件: 299 299 |
141 | OligoG (60 mg/ml) | - | - | - | - | 1件: 299 299 |
142 | OLIGOG CF-5/20 | - | - | - | - | 1件: 299 299 |
143 | OligoG CF-5/20 - 17.5 mg | - | - | - | - | 1件: 299 299 |
144 | OligoG CF-5/20, 17,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 |
145 | OligoG CF/20 - 27.5 mg | - | - | - | - | 1件: 299 299 |
146 | OligoG CF/20 - 37.5 mg | - | - | - | - | 1件: 299 299 |
147 | OligoG CF/20, 27,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 |
148 | OligoG CF/20, 37,5 mg, Hartkapsel mit Pulver zur Inhalation | - | - | - | - | 1件: 299 299 |
149 | OligoG DPI | - | - | - | - | 1件: 299 299 |
150 | OligoG-CF5/20, Alginate oligosaccharide (G-block) fragment | 1件: Alginic acid Alginic acid | 1件: D02324
D02324
| - | - | 1件: 299 299 |
151 | Oligomer of Sodium Alginate | 1件: Alginic acid Alginic acid | 1件: D02324
D02324
| - | - | 1件: 299 299 |
152 | Oligomero morfolino fosforodiamidato per skipping dell’esone 45 | - | - | - | - | 1件: 113 113 |
153 | Oligomero morfolino fosforodiamidato per skipping dell’esone 53 | - | - | - | - | 1件: 113 113 |
154 | Olikizumab | - | - | - | - | 1件: 46 46 |
155 | OLIPUDASE ALFA | 1件: Olipudase alfa Olipudase alfa | 1件: D10820
D10820
| 1件: SMPD1 SMPD1 💬 | 5件: Lysosome Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway 💬 | 1件: 19 19 |
156 | Olipudase alfa (GZ402665) | 1件: Olipudase alfa Olipudase alfa | 1件: D10820
D10820
| 1件: SMPD1 SMPD1 💬 | 5件: Lysosome Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway 💬 | 1件: 19 19 |
157 | Olipudase alfa (rhASM) | 1件: Olipudase alfa Olipudase alfa | 1件: D10820
D10820
| 1件: SMPD1 SMPD1 💬 | 5件: Lysosome Lysosome, Metabolic pathways, Necroptosis, Sphingolipid metabolism, Sphingolipid signaling pathway 💬 | 1件: 19 19 |
158 | Olive | 1件: Olea europaea leaf Olea europaea leaf | - | - | - | 5件: 13 13, 35, 49, 53, 162 |
159 | Olive oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 5件: 13 13, 35, 49, 53, 162 |
160 | Olokizumab | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 2件: 46 46, 96 |
161 | Olokizumab (OKZ) | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 96 96 |
162 | Olokizumab 120 mg | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
163 | Olokizumab 240 mg | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
164 | Olokizumab 60 mg | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
165 | Olokizumab 64 mg SC q2w | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
166 | Olokizumab 64 mg SC q4w | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
167 | Olokizumab 64mg q2w | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
168 | Olokizumab 64mg q4w | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
169 | Olokizumab q2w | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
170 | Olokizumab q4w | 1件: Olokizumab Olokizumab | 1件: D12487
D12487
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 46 46 |
171 | Olsalazine | 1件: Olsalazine Olsalazine | 1件: D08295
D08295
| - | - | 1件: 271 271 |
172 | Olumiant | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 4件: 46 46, 49, 93, 107 |
173 | Olumiant - EU/1/16/1170/001-008 | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 |
174 | Olumiant - EU/1/16/1170/009-016 | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 |
175 | OLUMIANT 4 mg | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
176 | OLUMIANT 4mg | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
177 | Oluminant | - | - | - | - | 1件: 107 107 |
178 | OM 89. | - | - | - | - | 1件: 46 46 |
179 | Omacor | - | - | - | - | 1件: 49 49 |
180 | Omadacycline | 1件: Omadacycline Omadacycline | 1件: D09647
D09647
| - | - | 1件: 299 299 |
181 | Omadacycline Injection [Nuzyra] | 1件: Omadacycline Omadacycline | 1件: D09647
D09647
| - | - | 1件: 299 299 |
182 | Omadacycline Oral Tablet [Nuzyra] | 1件: Omadacycline Omadacycline | 1件: D09647
D09647
| - | - | 1件: 299 299 |
183 | OMALIZUMAB | 1件: Omalizumab Omalizumab | 1件: D05251
D05251
| 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 7件: 46 46, 53, 65, 98, 162, 226, 299 |
184 | Omalizumab (Xolair) | 1件: Omalizumab Omalizumab | 1件: D05251
D05251
| 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 65 65 |
185 | Omaveloxolone | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
186 | Omaveloxolone Capsules, 10 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
187 | Omaveloxolone Capsules, 150 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
188 | Omaveloxolone Capsules, 160 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
189 | Omaveloxolone Capsules, 2.5 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
190 | Omaveloxolone Capsules, 20 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
191 | Omaveloxolone Capsules, 300 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
192 | Omaveloxolone Capsules, 40 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
193 | Omaveloxolone Capsules, 5 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
194 | Omaveloxolone Capsules, 80 mg | 1件: Omaveloxolone Omaveloxolone | 1件: D10964
D10964
| 1件: NFE2L2 NFE2L2 💬 | 7件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Lipid and atherosclerosis, Parkinson disease, Pathways in cancer, Protein processing in endoplasmic reticulum 💬 | 1件: 18 18 |
195 | OMB 157 | - | - | - | - | 1件: 13 13 |
196 | OMB157 | - | - | - | - | 1件: 13 13 |
197 | OMB157G | - | - | - | - | 1件: 13 13 |
198 | Omega 3 | - | - | - | - | 3件: 13 13, 53, 299 |
199 | Omega 3 fatty acid | - | - | - | - | 1件: 53 53 |
200 | Omega 3 Premium | - | - | - | - | 1件: 299 299 |
201 | Omega-3 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 7件: 13 13, 46, 49, 66, 79, 96, 299 |
202 | Omega-3 and Vitamin E supplementation | 2件: Omega-3 fatty acids Omega-3 fatty acids, Vitamin E | 1件: D02331
D02331
| - | - | 1件: 46 46 |
203 | Omega-3 fatty acid | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 46 46, 66 |
204 | Omega-3 fatty acid ethylester90 | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 66 66 |
205 | Omega-3 Fatty Acid Fish Oil Supplement | 2件: Fish oil Fish oil, Omega-3 fatty acids | - | - | - | 1件: 66 66 |
206 | Omega-3 fatty acids | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 2件: 13 13, 79 |
207 | Omega-3 triglycerides | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 299 299 |
208 | OMEGA-3-ACID TRIGLYCERIDES | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 299 299 |
209 | Omega3 | - | - | - | - | 1件: 46 46 |
210 | Omegaven | - | - | - | - | 1件: 96 96 |
211 | Omegaven (10% fish-oil emulsion | - | - | - | - | 1件: 46 46 |
212 | Omegaven 10% | - | - | - | - | 1件: 96 96 |
213 | Omeprazol | 1件: Omeprazole Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 294 294 |
214 | Omeprazole | 1件: Omeprazole Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 14件: 6 6, 8, 21, 46, 51, 85, 96, 97, 225, 271, 282, 294, 298, 299 |
215 | Omeprazole (UK licensed generic product) | 1件: Omeprazole Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 85 85 |
216 | Omeprazole 20mg | 1件: Omeprazole Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 51 51 |
217 | Omeprazole 40 mg | 1件: Omeprazole Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 96 96 |
218 | Omeprazole 40mg Capsule | 1件: Omeprazole Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 299 299 |
219 | Omeprazole Enteric Capsules | 1件: Omeprazole Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 46 46 |
220 | OMEPRAZOLE MAGNESIUM | 2件: Magnesium Magnesium, Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 225 225 |
221 | Omeprazole rectally 1mg/kg | 1件: Omeprazole Omeprazole | 1件: D00455
D00455
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 294 294 |
222 | Omidubicel | 1件: Omidubicel Omidubicel | - | - | - | 1件: 60 60 |
223 | Omidubicel (former CordIn) | 1件: Omidubicel Omidubicel | - | - | - | 1件: 60 60 |
224 | Omigapil | 1件: Omigapil Omigapil | - | - | - | 1件: 113 113 |
225 | OMNIPAQUE | 1件: Iohexol Iohexol | 1件: D01817
D01817
| - | - | 2件: 19 19, 222 |
226 | OMNIPAQUE - 300 MG I/ML SOLUZIONE INIETTABILE FLACONE IN POLIPROPILENE DA 50 ML | 1件: Iohexol Iohexol | 1件: D01817
D01817
| - | - | 1件: 222 222 |
227 | Omnitrop | - | - | - | - | 1件: 78 78 |
228 | OMNITROPE | 1件: Somatotropin Somatotropin | - | - | - | 2件: 78 78, 193 |
229 | Omnitrope® | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
230 | OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: D11531
D11531
| 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 1件: 109 109 |
231 | OMS643762 | - | - | - | - | 1件: 8 8 |
232 | OMS721 | - | - | - | - | 3件: 64 64, 66, 109 |
233 | OMS721 (narsoplimab) | 1件: Narsoplimab Narsoplimab | 1件: D11531
D11531
| 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 66 66, 222 |
234 | OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: D11531
D11531
| 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 64 64, 109 |
235 | OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody | 1件: Narsoplimab Narsoplimab | 1件: D11531
D11531
| 1件: MASP2 MASP2 💬 | 3件: Complement and coagulation cascades Complement and coagulation cascades, Coronavirus disease - COVID-19, Staphylococcus aureus infection 💬 | 2件: 64 64, 109 |
236 | OMS721 Drug Product 185 mg/mL | - | - | - | - | 1件: 109 109 |
237 | ON 01910.NA | - | - | - | - | 1件: 36 36 |
238 | Onabotulinum Toxin A | - | - | - | - | 1件: 226 226 |
239 | Onabotulinumtoxin A | - | - | - | - | 2件: 51 51, 226 |
240 | Onabotulinumtoxin A Injection | - | - | - | - | 1件: 6 6 |
241 | OnabotulinumtoxinA | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 4件: 6 6, 13, 149, 226 |
242 | Onabotulinumtoxina for Injection | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 149 149 |
243 | ONASEMNOGENE ABEPARVOVEC | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: D11559
D11559
| 1件: SMN1 SMN1 💬 | - | 1件: 3 3 |
244 | Onasemnogene Abeparvovec-xioi | 1件: Onasemnogene abeparvovec Onasemnogene abeparvovec | 1件: D11559
D11559
| 1件: SMN1 SMN1 💬 | - | 1件: 3 3 |
245 | Once a day Trientine | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 171 171 |
246 | Once daily subcutaneous injection of Genotropin | 1件: Somatotropin Somatotropin | - | - | - | 1件: 78 78 |
247 | Once weekly subcutaneous injection of TransCon hGH | - | - | - | - | 1件: 78 78 |
248 | Once-daily insulin detemir | 1件: Insulin detemir Insulin detemir | 1件: D04539
D04539
| 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 |
249 | Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter | 2件: Iodide Iodide, Sodium iodide | 3件: D04874
D04874
,
D05328
,
D05863
| - | - | 1件: 34 34 |
250 | Oncovin | - | - | - | - | 1件: 34 34 |
251 | Oncoxin + Viusid | - | - | - | - | 1件: 46 46 |
252 | Ondansetron | 1件: Ondansetron Ondansetron | 1件: D00456
D00456
| 5件: HTR3A HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 | 2件: Serotonergic synapse Serotonergic synapse, Taste transduction 💬 | 3件: 6 6, 97, 107 |
253 | Ondansetron 8 mg film-coated tablets | 1件: Ondansetron Ondansetron | 1件: D00456
D00456
| 5件: HTR3A HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 | 2件: Serotonergic synapse Serotonergic synapse, Taste transduction 💬 | 1件: 6 6 |
254 | Ondansetron hydrochloride dihydrate | 1件: Ondansetron Ondansetron | 1件: D00456
D00456
| 5件: HTR3A HTR3A, HTR3B, HTR3C, HTR3D, HTR3E 💬 | 2件: Serotonergic synapse Serotonergic synapse, Taste transduction 💬 | 2件: 6 6, 97 |
255 | One 20cm2/10cm2 autologous skin sheet graft | - | - | - | - | 1件: 160 160 |
256 | One additional blood sample during a planned blood test | - | - | - | - | 1件: 266 266 |
257 | One Alpha | - | - | - | - | 2件: 50 50, 107 |
258 | One Alpha Drops | - | - | - | - | 2件: 50 50, 107 |
259 | One-alpha | 1件: Alfacalcidol Alfacalcidol | 1件: D01518
D01518
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 50 50, 107 |
260 | One-Alpha drops | 1件: Alfacalcidol Alfacalcidol | 1件: D01518
D01518
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 2件: 50 50, 107 |
261 | Ongentys | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
262 | Ongentys 50 mg capsule rigide | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
263 | Ongentys 50 mg hard capsules | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
264 | Ongentys 50mg | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
265 | Only 1 arm: treatment with MSC-AFP | - | - | - | - | 1件: 96 96 |
266 | Only medicinal products registered in Austria will be used in this clinical trial. | - | - | - | - | 1件: 78 78 |
267 | Only medicinal products registered in Germany will be used in this clinical trial | - | - | - | - | 1件: 78 78 |
268 | ONO-2160/CD | - | - | - | - | 1件: 6 6 |
269 | ONO-2370 | - | - | - | - | 1件: 6 6 |
270 | ONO-2506 | - | - | - | - | 1件: 2 2 |
271 | ONO-2506PO | - | - | - | - | 2件: 2 2, 6 |
272 | ONO-4059 | 1件: Tirabrutinib Tirabrutinib | - | - | - | 1件: 35 35 |
273 | ONO-4641 | - | - | - | - | 1件: 13 13 |
274 | ONO-4641/ MSC2430913A | - | - | - | - | 1件: 13 13 |
275 | ONO-4641/MSC2430913A | - | - | - | - | 1件: 13 13 |
276 | Ontamalimab | 1件: Ontamalimab Ontamalimab | - | - | - | 2件: 96 96, 97 |
277 | Opana | 1件: Oxymorphone Oxymorphone | 1件: D08323
D08323
| 1件: OPRM1 OPRM1 💬 | 3件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction 💬 | 1件: 70 70 |
278 | OPC | - | - | - | - | 1件: 6 6 |
279 | OPC-41061 | - | - | - | - | 1件: 67 67 |
280 | OPC-41061 (tolvaptan) | 1件: Tolvaptan Tolvaptan | 1件: D01213
D01213
| 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 |
281 | OPC-6535 | - | - | - | - | 2件: 96 96, 97 |
282 | OPC-6535 Tablets (drug) | - | - | - | - | 1件: 97 97 |
283 | OPC-6535(Tetomilast) | 1件: Tetomilast Tetomilast | - | - | - | 2件: 96 96, 97 |
284 | Open Label (Avatrombopag tablets) | 1件: Avatrombopag Avatrombopag | 1件: D10306
D10306
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 1件: 63 63 |
285 | Open label - AL001 | 1件: Latozinemab Latozinemab | 1件: D12427
D12427
| 1件: SORT1 SORT1 💬 | 3件: Cholesterol metabolism Cholesterol metabolism, Lysosome, Neurotrophin signaling pathway 💬 | 1件: 127 127 |
286 | Open label Namilumab | 1件: Namilumab Namilumab | - | - | - | 1件: 84 84 |
287 | Open label RAD001 (only used for post-extension phase) | - | - | - | - | 1件: 158 158 |
288 | Open Label Topical Beremagene Geperpavec (B-VEC) | - | - | - | - | 1件: 36 36 |
289 | Open-label Abatacept | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
290 | Open-label Adalimumab | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
291 | Open-Label CDCA 250 mg TID | 1件: Chenodeoxycholic acid Chenodeoxycholic acid | 1件: D00163
D00163
| 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 263 263 |
292 | Open-label PTH(1-84) | - | - | - | - | 1件: 235 235 |
293 | Open-labelAdalimumabRescue | - | - | - | - | 1件: 46 46 |
294 | OpenBiome FMT product FMP250 | - | - | - | - | 1件: 65 65 |
295 | Ophthalmic Emulsion | - | - | - | - | 2件: 51 51, 53 |
296 | OPICAPONE | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
297 | Opicapone (OPC) | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
298 | Opicapone 50 mg | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
299 | Opicapone 50 mg hard capsules | 1件: Opicapone Opicapone | 1件: D10825
D10825
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
300 | Opicinumab | 1件: Opicinumab Opicinumab | 1件: D11767
D11767
| 1件: LINGO1 LINGO1 💬 | - | 1件: 13 13 |
301 | OPL-CCL2-LPM | - | - | - | - | 1件: 66 66 |
302 | Oprelvekin | 1件: Oprelvekin Oprelvekin | 1件: D05266
D05266
| 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 |
303 | Oprelvekin, Interleukin 11, IL-11 | 1件: Oprelvekin Oprelvekin | 1件: D05266
D05266
| 1件: IL11RA IL11RA 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway 💬 | 1件: 288 288 |
304 | OPRX-106 | - | - | - | - | 1件: 97 97 |
305 | OPRX-106 (plant cells expressing TNFR-Fc) 2mg | - | - | - | - | 1件: 97 97 |
306 | OPRX-106 (plant cells expressing TNFR-Fc) 8mg | - | - | - | - | 1件: 97 97 |
307 | OPS-2071 | - | - | - | - | 1件: 96 96 |
308 | OPS-2071 150 mg | - | - | - | - | 1件: 96 96 |
309 | OPS-2071 300 mg | - | - | - | - | 1件: 96 96 |
310 | OPS-2071 600 mg | - | - | - | - | 1件: 96 96 |
311 | Opsumit | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 86 86, 88, 210 |
312 | Opsumit (macitentan) | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
313 | Opsumit 10 Mg Tablet | - | - | - | - | 1件: 51 51 |
314 | Opsumit® | 1件: Macitentan Macitentan | 1件: D10135
D10135
| 2件: EDNRA EDNRA, EDNRB 💬 | 9件: Calcium signaling pathway Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 86 86, 88, 210 |
315 | Optimal drug therapy | - | - | - | - | 1件: 6 6 |
316 | Optimized antiparkinsonian treatment | - | - | - | - | 1件: 6 6 |
317 | Optimized Medical Treatment | - | - | - | - | 1件: 6 6 |
318 | Optimized oral treatment | - | - | - | - | 1件: 6 6 |
319 | Optinate 5 mg filmcoated tablets | - | - | - | - | 1件: 274 274 |
320 | Optional pharmacogenetic assessment | - | - | - | - | 1件: 6 6 |
321 | Optison | 1件: Perflutren Perflutren | 1件: D01738
D01738
| - | - | 1件: 96 96 |
322 | Optivate | - | - | - | - | 1件: 288 288 |
323 | Optivate® (Human Coagulation Factor VIII) | 2件: Antihemophilic factor human Antihemophilic factor human, Beroctocog alfa | - | - | - | 1件: 288 288 |
324 | Oral | - | - | - | - | 2件: 46 46, 271 |
325 | Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone | 2件: Mesalazine Mesalazine, Methylprednisolone | 2件: D00377
D00377
,
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
326 | Oral all-trans retinoic acid (ATRA) | 1件: Tretinoin Tretinoin | 1件: D00094
D00094
| 3件: PML PML, RARA, RARB 💬 | 12件: Acute myeloid leukemia Acute myeloid leukemia, Endocytosis, Estrogen signaling pathway, Gastric cancer, Herpes simplex virus 1 infection, Influenza A, Non-small cell lung cancer, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Transcriptional misregulation in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 94 94 |
327 | Oral anticoagulant treatment | - | - | - | - | 1件: 86 86 |
328 | Oral Aztreonam | 1件: Aztreonam Aztreonam | 1件: D00240
D00240
| - | - | 1件: 299 299 |
329 | Oral bovine type I collagen | 1件: Bovine type I collagen Bovine type I collagen | - | - | - | 1件: 51 51 |
330 | Oral bovine type II collagen | - | - | - | - | 1件: 46 46 |
331 | Oral Budesonide | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
332 | Oral Budesonide Suspension (MB-9) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
333 | Oral Budesonide Suspension (OBS) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
334 | Oral ciprofloxacin | 1件: Ciprofloxacin Ciprofloxacin | 1件: D00186
D00186
| - | - | 1件: 299 299 |
335 | Oral ciprofloxacin plus inhaled colistin | 2件: Ciprofloxacin Ciprofloxacin, Colistin | 2件: D00186
D00186
,
D07746
| - | - | 1件: 299 299 |
336 | Oral corticosteroids | - | - | - | - | 5件: 13 13, 46, 97, 171, 251 |
337 | Oral corticosteroids (OCS) | - | - | - | - | 1件: 162 162 |
338 | Oral cromolyn sodium | 1件: Cromoglicic acid Cromoglicic acid | 1件: D07753
D07753
| - | - | 1件: 98 98 |
339 | Oral Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 222 222 |
340 | Oral drops solution | - | - | - | - | 1件: 28 28 |
341 | Oral ERA | - | - | - | - | 1件: 86 86 |
342 | Oral erythromycin | 1件: Erythromycin Erythromycin | 1件: D00140
D00140
| - | - | 1件: 36 36 |
343 | Oral escitalopram | 1件: Escitalopram Escitalopram | 1件: D07913
D07913
| 1件: SLC6A4 SLC6A4 💬 | 2件: Serotonergic synapse Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 6 6 |
344 | Oral Glucose Tolerance test (75g 2-hour) | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 299 299 |
345 | Oral Glutathione | 1件: Glutathione Glutathione | 2件: D00014
D00014
,
D00031
| - | - | 1件: 299 299 |
346 | Oral Iron | 1件: Iron Iron | - | - | - | 2件: 97 97, 254 |
347 | Oral levodopa and carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
348 | Oral Levodopa/Carbidopa | 2件: Carbidopa Carbidopa, Levodopa | 2件: D00059
D00059
,
D00558
| 6件: DDC DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 16件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway 💬 | 1件: 6 6 |
349 | Oral LEVOSIMENDAN | 1件: Levosimendan Levosimendan | 1件: D04720
D04720
| 2件: PDE3A PDE3A, PDE3B 💬 | 11件: Apelin signaling pathway Apelin signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Progesterone-mediated oocyte maturation, Purine metabolism, Regulation of lipolysis in adipocytes, Renin secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 2 2 |
350 | Oral lipoic acid (LA) | 1件: Lipoic acid Lipoic acid | - | - | - | 1件: 13 13 |
351 | Oral methotrexate | 1件: Methotrexate Methotrexate | 1件: D00142
D00142
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
352 | Oral Methylprednisolone 625 mg/24h x3 days | 1件: Methylprednisolone Methylprednisolone | 1件: D00407
D00407
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 13 13 |
353 | Oral migalastat HCl | 1件: Migalastat Migalastat | 1件: D10359
D10359
| - | - | 1件: 19 19 |
354 | Oral nutritional supplementation | - | - | - | - | 1件: 2 2 |
355 | Oral OKT3 | - | - | - | - | 1件: 97 97 |
356 | Oral PDE5 inhibitors | - | - | - | - | 1件: 86 86 |
357 | Oral Pednisolone | - | - | - | - | 1件: 145 145 |
358 | Oral prednisolone | 1件: Prednisolone Prednisolone | 1件: D00472
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 49 49, 96, 145 |
359 | Oral Prednisone 5mg | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 49 49 |
360 | Oral reduced l-glutathione | 1件: Glutathione Glutathione | 2件: D00014
D00014
,
D00031
| - | - | 1件: 299 299 |
361 | Oral roflumilast | 1件: Roflumilast Roflumilast | 1件: D05744
D05744
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 299 299 |
362 | Oral SCIO-469 capsule | - | - | - | - | 1件: 46 46 |
363 | Oral selexipag (Uptravi) | 1件: Selexipag Selexipag | 1件: D09994
D09994
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
364 | Oral sildenafil | 1件: Sildenafil Sildenafil | 1件: D08514
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
365 | Oral sirolimus | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 |
366 | Oral THC | - | - | - | - | 1件: 13 13 |
367 | Oral treprostinil | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 2件: 51 51, 86 |
368 | Oral treprostinil (UT-15C) Sustained Release Tablets | 1件: Treprostinil Treprostinil | 1件: D06213
D06213
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
369 | Oral Vancomycin | 1件: Vancomycin Vancomycin | 1件: D00212
D00212
| - | - | 2件: 94 94, 296 |
370 | Oral Viscous Budesonide | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
371 | Oral Viscous Budesonide (OVB) | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
372 | Orally disintegrating selegiline (Zelapar) | 1件: Selegiline Selegiline | 1件: D03731
D03731
| 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
373 | OraPlus | - | - | - | - | 1件: 310 310 |
374 | Orbcel-C | 1件: Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells | - | - | - | 2件: 94 94, 95 |
375 | ORE1001 | - | - | - | - | 1件: 97 97 |
376 | Orelabrutinib | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 4件: 13 13, 49, 61, 63 |
377 | Orelabrutinib (High Dose) | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 49 49 |
378 | Orelabrutinib (Low Dose) | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 49 49 |
379 | Orelabrutinib( higher dose) | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 63 63 |
380 | Orelabrutinib( lower dose) | 1件: Orelabrutinib Orelabrutinib | 1件: D12160
D12160
| 1件: BTK BTK 💬 | 7件: B cell receptor signaling pathway B cell receptor signaling pathway, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Platelet activation, Primary immunodeficiency 💬 | 1件: 63 63 |
381 | ORENCIA | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 14件: 44 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 160, 222, 271 |
382 | Orencia (abatacept) | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
383 | Orencia (trade name) | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 50 50 |
384 | Orencia 125 mg | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
385 | ORENCIA 125 mg solution for injection | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
386 | ORENCIA 125 mg solution for injection in pre-filled syringe | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 3件: 46 46, 49, 53 |
387 | ORENCIA 125 mg, solution injectable en seringue préremplie | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
388 | ORENCIA 250 mg polvo para concentrado para sol. para perfusión | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
389 | ORENCIA 250mg powder for concentrate for solution for infusion | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
390 | Orencia abatacept | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
391 | ORENCIA Subcutaneous Injection | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
392 | ORENCIA*IV 2FL 250MG+2SIR | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 46 46 |
393 | Orencia® (Abatacept) | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 95 95 |
394 | ORENCIA® 125 mg solution for injection in pre-filled syringe | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 13件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Virion - Adenovirus 💬 | 1件: 65 65 |
395 | Orfadin | 1件: Nitisinone Nitisinone | 1件: D05177
D05177
| 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 2件: 6 6, 241 |
396 | Orfadin oral suspension 4mg/ml | 1件: Nitisinone Nitisinone | 1件: D05177
D05177
| 1件: HPD HPD 💬 | 5件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Phenylalanine metabolism, Tyrosine metabolism, Ubiquinone and other terpenoid-quinone biosynthesis 💬 | 1件: 241 241 |
397 | Orfiril Saft | - | - | - | - | 1件: 3 3 |
398 | Originator | - | - | - | - | 2件: 46 46, 271 |
399 | Originator (legacy) drug | - | - | - | - | 4件: 46 46, 96, 97, 271 |
400 | Originator adalimumab | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 107 107 |
401 | Originator rituximab - Rituxan ® or MabThera ® | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
402 | ORILANOLIMAB | 1件: Orilanolimab Orilanolimab | 1件: D12144
D12144
| 1件: FCGRT FCGRT 💬 | - | 1件: 61 61 |
403 | ORIN1001 | - | - | - | - | 1件: 85 85 |
404 | Orkambi | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
405 | Orkambi 100 mg/125 mg film-coated tablets | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
406 | Orkambi 200 mg/125 mg film-coated tablets | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
407 | Orkambi: contains lumacaftor and ivacaftor | 2件: Ivacaftor Ivacaftor, Lumacaftor | 2件: D09916
D09916
,
D10134
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
408 | Orkambi® | 1件: Ivacaftor Ivacaftor | 1件: D09916
D09916
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
409 | ORL-1B | - | - | - | - | 1件: 255 255 |
410 | ORM-12471 | - | - | - | - | 1件: 51 51 |
411 | ORM-12471 30mg | - | - | - | - | 1件: 51 51 |
412 | ORM-12741 | 1件: ORM-12741 ORM-12741 | - | - | - | 1件: 51 51 |
413 | ORMONE PARATIROIDEO DA DNA RICOMBINANTE | - | - | - | - | 1件: 235 235 |
414 | Orncia | - | - | - | - | 1件: 46 46 |
415 | Ornithine | 1件: Ornithine Ornithine | 1件: D08302
D08302
| - | - | 2件: 245 245, 251 |
416 | Ornithine alpha ketoglutarate | 1件: Ornithine Ornithine | 1件: D08302
D08302
| - | - | 1件: 245 245 |
417 | Ornithine transcarbamylase vector | 1件: Ornithine Ornithine | 1件: D08302
D08302
| - | - | 1件: 251 251 |
418 | OROCAL | - | - | - | - | 1件: 75 75 |
419 | Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg | 3件: Estradiol Estradiol, Ethinylestradiol, Norgestimate | 3件: D00105
D00105
,
D00554
,
D05209
| 3件: ESR1 ESR1, ESR2, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 299 299 |
420 | Ortho-novum | 1件: Mestranol Mestranol | 1件: D00575
D00575
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 2件: 46 46, 49 |
421 | Ortho-Novum 777 | 1件: Mestranol Mestranol | 1件: D00575
D00575
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 49 49 |
422 | Ortho-Novum® 1/35 | 1件: Mestranol Mestranol | 1件: D00575
D00575
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 46 46 |
423 | ORVEPITANT | 1件: Orvepitant Orvepitant | 1件: D09650
D09650
| 1件: TACR1 TACR1 💬 | 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 85 85 |
424 | Orvepitant Maleate | 1件: Orvepitant Orvepitant | 1件: D09650
D09650
| 1件: TACR1 TACR1 💬 | 2件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 85 85 |
425 | ORY2001 | - | - | - | - | 1件: 13 13 |
426 | OS440 | - | - | - | - | 1件: 13 13 |
427 | OSCN- | - | - | - | - | 1件: 299 299 |
428 | OSE-127 | - | - | - | - | 2件: 53 53, 97 |
429 | Oseltamivir | 1件: Oseltamivir Oseltamivir | 1件: D08306
D08306
| - | - | 2件: 97 97, 299 |
430 | OSILODROSTAT | 1件: Osilodrostat Osilodrostat | 1件: D11061
D11061
| 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 |
431 | Osilodrostat 10mg | 1件: Osilodrostat Osilodrostat | 1件: D11061
D11061
| 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 |
432 | Osilodrostat 1mg | 1件: Osilodrostat Osilodrostat | 1件: D11061
D11061
| 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 |
433 | Osilodrostat 20mg | 1件: Osilodrostat Osilodrostat | 1件: D11061
D11061
| 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 |
434 | Osilodrostat 5mg | 1件: Osilodrostat Osilodrostat | 1件: D11061
D11061
| 1件: CYP11B2 CYP11B2 💬 | 3件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Metabolic pathways, Steroid hormone biosynthesis 💬 | 1件: 75 75 |
435 | Osmohale | - | - | - | - | 1件: 299 299 |
436 | OsrhAAT 1 mg/kg IV | - | - | - | - | 1件: 231 231 |
437 | OsrhAAT 10 mg/kg IV | - | - | - | - | 1件: 231 231 |
438 | OsrhAAT 20 mg/kg IV | - | - | - | - | 1件: 231 231 |
439 | OsrhAAT 3 mg/kg IV | - | - | - | - | 1件: 231 231 |
440 | OsrhAAT 40 mg/kg IV | - | - | - | - | 1件: 231 231 |
441 | OsrhAAT 60 mg/kg IV | - | - | - | - | 1件: 231 231 |
442 | Ossein hydroxyapatite | - | - | - | - | 1件: 75 75 |
443 | OSSIDO DI AZOTO | - | - | - | - | 1件: 294 294 |
444 | Ossido Nitrico | - | - | - | - | 1件: 86 86 |
445 | OSSITOCINA | - | - | - | - | 1件: 193 193 |
446 | Ossium vBM-MSC | - | - | - | - | 1件: 96 96 |
447 | OSSM-001 | - | - | - | - | 1件: 96 96 |
448 | OST-122 | - | - | - | - | 1件: 97 97 |
449 | Osteoblast biology study | - | - | - | - | 1件: 238 238 |
450 | Osteomalacia | - | - | - | - | 1件: 238 238 |
451 | Osteopetrosis Haploidentical Only Preparative Regimen | - | - | - | - | 5件: 19 19, 20, 125, 234, 326 |
452 | Osteopetrosis Only Preparative Regimen | - | - | - | - | 5件: 19 19, 20, 125, 234, 326 |
453 | OSTEOPOR | - | - | - | - | 1件: 75 75 |
454 | OSU 6162 similar to (-)-OSU 6162 | - | - | - | - | 1件: 6 6 |
455 | OSU6162 similar to (-)-OSU 6162 | - | - | - | - | 2件: 6 6, 8 |
456 | OT | - | - | - | - | 1件: 193 193 |
457 | Otelixizumab | 1件: Otelixizumab Otelixizumab | 1件: D08959
D08959
| 3件: CD3D CD3D, CD3E, CD3G 💬 | 11件: Chagas disease Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 46 46 |
458 | Otezla | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 3件: 56 56, 107, 162 |
459 | OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA 30 MG | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 2件: 56 56, 107 |
460 | OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE | 1件: Apremilast Apremilast | 1件: D08860
D08860
| 4件: PDE4A PDE4A, PDE4B, PDE4C, PDE4D 💬 | 5件: Metabolic pathways Metabolic pathways, Morphine addiction, Parathyroid hormone synthesis, secretion and action, Purine metabolism, cAMP signaling pathway 💬 | 1件: 107 107 |
461 | Other analgesics and antipyretics | - | - | - | - | 1件: 13 13 |
462 | Other antiepileptics | - | - | - | - | 1件: 140 140 |
463 | Other Biologic Therapies | - | - | - | - | 2件: 96 96, 97 |
464 | Other biological agent | - | - | - | - | 2件: 46 46, 96 |
465 | Other Biologics | - | - | - | - | 1件: 46 46 |
466 | Other COX-2 inhibitor | - | - | - | - | 1件: 271 271 |
467 | Other Cox-2 inhibitors | - | - | - | - | 1件: 271 271 |
468 | Other Crystalloid | - | - | - | - | 1件: 296 296 |
469 | Other disease-modifying therapy | - | - | - | - | 1件: 13 13 |
470 | Other H1 antagonist | - | - | - | - | 1件: 13 13 |
471 | Other hematological Agents | - | - | - | - | 1件: 65 65 |
472 | OTHER NERVOUS SYSTEM DRUGS | - | - | - | - | 2件: 6 6, 13 |
473 | Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac | 1件: Etodolac Etodolac | 1件: D00315
D00315
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 46 46 |
474 | Other Non-selective NSAIDs | - | - | - | - | 1件: 271 271 |
475 | Other non-sponsor pancreatic enzyme replacement therapy | - | - | - | - | 1件: 299 299 |
476 | Other Parkinson's Disease treatments | - | - | - | - | 1件: 6 6 |
477 | Other respiratory system products | - | - | - | - | 1件: 299 299 |
478 | OTHER SOURCES | - | - | - | - | 1件: 228 228 |
479 | Other vasodilator | - | - | - | - | 1件: 51 51 |
480 | OTILIMAB | 1件: Otilimab Otilimab | 1件: D11343
D11343
| 1件: CSF2 CSF2 💬 | 16件: Acute myeloid leukemia Acute myeloid leukemia, Amoebiasis, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, IL-17 signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Natural killer cell mediated cytotoxicity, Rheumatoid arthritis, Shigellosis, T cell receptor signaling pathway, TNF signaling pathway, Transcriptional misregulation in cancer 💬 | 1件: 46 46 |
481 | Otilimab (GSK3196165) | 1件: Otilimab Otilimab | 1件: D11343
D11343
| 1件: CSF2 CSF2 💬 | 16件: Acute myeloid leukemia Acute myeloid leukemia, Amoebiasis, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, IL-17 signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Natural killer cell mediated cytotoxicity, Rheumatoid arthritis, Shigellosis, T cell receptor signaling pathway, TNF signaling pathway, Transcriptional misregulation in cancer 💬 | 1件: 46 46 |
482 | OTL-101 | - | - | - | - | 1件: 65 65 |
483 | OTL-103 | - | - | - | - | 1件: 65 65 |
484 | OTL-103 Dispersion for Infusion | - | - | - | - | 1件: 65 65 |
485 | OTL-200 | - | - | - | - | 1件: 19 19 |
486 | OTL-200 Dispersion for Infusion | - | - | - | - | 1件: 19 19 |
487 | OTL-200 Gene Therapy | - | - | - | - | 1件: 19 19 |
488 | OTL38 | - | - | - | - | 1件: 46 46 |
489 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 |
490 | OV101 | - | - | - | - | 2件: 201 201, 206 |
491 | OV101 (gaboxadol) | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 206 206 |
492 | OV101 Regimen 1 | - | - | - | - | 1件: 201 201 |
493 | OV101 regimen 2 | - | - | - | - | 1件: 201 201 |
494 | Ova-Treg | - | - | - | - | 1件: 96 96 |
495 | Ovasave | - | - | - | - | 1件: 96 96 |
496 | OVASTAT | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
497 | Ovastat 1000 | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
498 | Ovastat 1000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 1件: 65 65 |
499 | Ovastat 1000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 1件: 65 65 |
500 | Ovastat 5000 | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
501 | Ovastat 5000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 1件: 65 65 |
502 | Ovastat 5000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 1件: 65 65 |
503 | Over encapsulated prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 41 41 |
504 | Over the counter DHA/EPA dietary supplementation | - | - | - | - | 1件: 301 301 |
505 | Over-encapsulated 150 mg Irbesartan Tablets | 1件: Irbesartan Irbesartan | 1件: D00523
D00523
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 66 66 |
506 | Over-encapsulated 75 mg Irbesartan Tablets | 1件: Irbesartan Irbesartan | 1件: D00523
D00523
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 222 222 |
507 | Over-encapsulated Entacapone Tablets | 1件: Entacapone Entacapone | 1件: D00781
D00781
| 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 |
508 | Over-encapsulated Irbesartan | 1件: Irbesartan Irbesartan | 1件: D00523
D00523
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 |
509 | Over-encapsulated Irbesartan Tablets | 1件: Irbesartan Irbesartan | 1件: D00523
D00523
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 66 66, 222 |
510 | Over-encapsulated Modafinil | 1件: Modafinil Modafinil | 1件: D01832
D01832
| - | - | 1件: 6 6 |
511 | Overencapsulated Azathioprine (Imuran) 50 mg Tablet | 1件: Azathioprine Azathioprine | 1件: D00238
D00238
| - | - | 1件: 97 97 |
512 | Overencapsulated mesalazine tablets | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 97 97 |
513 | Overencapsulated Prednisolone Tablets | 1件: Prednisolone Prednisolone | 1件: D00472
D00472
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
514 | Ovine Corticotropin-Releasing Hormone (oCRH) | 2件: Corticorelin Corticorelin, Corticotropin | 2件: D00146
D00146
,
D03905
| 3件: CRHR1 CRHR1, CRHR2, MC2R 💬 | 6件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 75 75 |
515 | Oxadrop | - | - | - | - | 1件: 96 96 |
516 | Oxaloacetate | 1件: Oxaloacetic acid Oxaloacetic acid | - | - | - | 2件: 6 6, 11 |
517 | Oxaloacetate (OAA) | 1件: Oxaloacetic acid Oxaloacetic acid | - | - | - | 1件: 6 6 |
518 | Oxandrolone | 1件: Oxandrolone Oxandrolone | 1件: D00462
D00462
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 2件: 211 211, 285 |
519 | Oxanest | - | - | - | - | 1件: 70 70 |
520 | Oxatomide | 1件: Oxatomide Oxatomide | 1件: D01773
D01773
| 1件: ALOX5 ALOX5 💬 | 6件: Arachidonic acid metabolism Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis 💬 | 1件: 113 113 |
521 | Oxatomide (tinset) | 1件: Oxatomide Oxatomide | 1件: D01773
D01773
| 1件: ALOX5 ALOX5 💬 | 6件: Arachidonic acid metabolism Arachidonic acid metabolism, Fc epsilon RI signaling pathway, Metabolic pathways, Ovarian steroidogenesis, Serotonergic synapse, Toxoplasmosis 💬 | 1件: 113 113 |
522 | OXB-102 | - | - | - | - | 1件: 6 6 |
523 | Oxcarbazepine | 1件: Oxcarbazepine Oxcarbazepine | 1件: D00533
D00533
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 13 13 |
524 | Oxepa | - | - | - | - | 1件: 2 2 |
525 | OXERVATE | 1件: Cenegermin Cenegermin | 1件: D11028
D11028
| 1件: NGFR NGFR 💬 | 9件: Apoptosis - multiple species Apoptosis - multiple species, Cytokine-cytokine receptor interaction, MAPK signaling pathway, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Transcriptional misregulation in cancer, Virion - Lyssavirus 💬 | 1件: 53 53 |
526 | OXICODONE DC.IT | - | - | - | - | 1件: 46 46 |
527 | Oxiconazole | 1件: Oxiconazole Oxiconazole | 1件: D08313
D08313
| - | - | 1件: 160 160 |
528 | Oxiklorin | - | - | - | - | 2件: 13 13, 46 |
529 | Oxine | 1件: Oxyquinoline Oxyquinoline | 1件: D05321
D05321
| - | - | 1件: 13 13 |
530 | OXN 10 mg / 5 mg PR | - | - | - | - | 1件: 6 6 |
531 | OXN 10/5 mg PR | - | - | - | - | 1件: 226 226 |
532 | OXN 20 mg / 10 mg PR | - | - | - | - | 1件: 6 6 |
533 | OXN 20/10 mg PR | - | - | - | - | 1件: 226 226 |
534 | OXN 5 mg/2.5 mg PR | - | - | - | - | 1件: 6 6 |
535 | OXN 5/2.5 mg PR | - | - | - | - | 1件: 226 226 |
536 | Oxybate | 1件: gamma-Hydroxybutyric acid gamma-Hydroxybutyric acid | - | - | - | 2件: 6 6, 149 |
537 | Oxybuprocaine | 1件: Oxybuprocaine Oxybuprocaine | 1件: D08319
D08319
| 5件: SCN1A SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 3件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction 💬 | 1件: 6 6 |
538 | Oxybutynin | 1件: Oxybutynin Oxybutynin | 1件: D00465
D00465
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 3件: 6 6, 13, 53 |
539 | Oxybutynin and darifenacin | 2件: Darifenacin Darifenacin, Oxybutynin | 2件: D00465
D00465
,
D03654
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
540 | Oxybutynin hydrochloride | 1件: Oxybutynin Oxybutynin | 1件: D00465
D00465
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 2件: 6 6, 13 |
541 | Oxybutynin, tolterodine, solifenacin | 3件: Oxybutynin Oxybutynin, Solifenacin, Tolterodine | 3件: D00465
D00465
,
D00646
,
D08522
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 53 53 |
542 | OXYCODO | - | - | - | - | 1件: 6 6 |
543 | Oxycodone | 1件: Oxycodone Oxycodone | 1件: D05312
D05312
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 5件: 6 6, 13, 70, 226, 298 |
544 | Oxycodone Depot ”Sandoz”, depot tablets | 1件: Oxycodone Oxycodone | 1件: D05312
D05312
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 298 298 |
545 | OXYCODONE HYDROCHLORIDE | 1件: Oxycodone Oxycodone | 1件: D05312
D05312
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 4件: 6 6, 70, 226, 298 |
546 | Oxycodone naloxone prolonged release tablets | 2件: Naloxone Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 |
547 | Oxycodone Orion | 1件: Oxycodone Oxycodone | 1件: D05312
D05312
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 70 70 |
548 | Oxycodone/naloxone prolonged release t | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 |
549 | Oxycodone/Naloxone Prolonged Release tablets | 2件: Naloxone Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
550 | Oxycodone/naloxone prolonged release tablets 10 mg /5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
551 | Oxycodone/naloxone prolonged release tablets 10/5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 |
552 | Oxycodone/naloxone prolonged release tablets 20 mg /10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
553 | Oxycodone/naloxone prolonged release tablets 20/10 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 |
554 | Oxycodone/naloxone prolonged release tablets 5 mg /2.5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
555 | Oxycodone/naloxone prolonged release tablets 5/2.5 mg | 3件: Manganese citrate Manganese citrate, Naloxone, Oxycodone | 2件: D05312
D05312
,
D08249
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 226 226 |
556 | Oxycodonhydrochlorid ”Lannacher”, depot tablets | - | - | - | - | 1件: 298 298 |
557 | Oxycontin LP 10mg | 1件: Oxycodone Oxycodone | 1件: D05312
D05312
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
558 | Oxycontin LP 20mg | 1件: Oxycodone Oxycodone | 1件: D05312
D05312
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
559 | Oxycontin LP 5mg | 1件: Oxycodone Oxycodone | 1件: D05312
D05312
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
560 | Oxygen | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 13件: 6 6, 49, 70, 85, 86, 88, 90, 96, 168, 193, 271, 299, 330 |
561 | Oxygen 40 % | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 85 85 |
562 | Oxygen supplementation | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 86 86 |
563 | Oxygen, liquid | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 2件: 86 86, 88 |
564 | Oxygen-15 Water | 2件: Oxygen Oxygen, Water | 2件: D00001
D00001
,
D00003
| - | - | 1件: 6 6 |
565 | Oxymatrine | 1件: Oxymatrine Oxymatrine | - | - | - | 1件: 37 37 |
566 | Oxynorm | - | - | - | - | 1件: 298 298 |
567 | Oxytocin | 1件: Oxytocin Oxytocin | 1件: D00089
D00089
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 7件: 6 6, 72, 127, 168, 193, 206, 226 |
568 | Oxytocin (OXT) continuous | 1件: Oxytocin Oxytocin | 1件: D00089
D00089
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 193 193 |
569 | Oxytocin 24IU | 1件: Oxytocin Oxytocin | 1件: D00089
D00089
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 206 206 |
570 | Oxytocin 48IU | 1件: Oxytocin Oxytocin | 1件: D00089
D00089
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 206 206 |
571 | Oxytocin nasal spray | 1件: Oxytocin Oxytocin | 1件: D00089
D00089
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 2件: 72 72, 193 |
572 | OXYTOCIN SYNTHETIC | 1件: Oxytocin Oxytocin | 1件: D00089
D00089
| 1件: OXTR OXTR 💬 | 4件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Oxytocin signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
573 | Oyster | 1件: Oyster Oyster | - | - | - | 1件: 84 84 |
574 | Ozanezumab | 1件: Ozanezumab Ozanezumab | 1件: D10331
D10331
| 1件: RTN4 RTN4 💬 | 1件: Alzheimer disease Alzheimer disease 💬 | 1件: 2 2 |
575 | Ozanimod | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 13 13, 96, 97 |
576 | Ozanimod 0.5 mg | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
577 | Ozanimod 1 mg | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
578 | Ozanimod HCI | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
579 | Ozanimod HCL | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 97 |
580 | Ozanimod hydrochloride | 1件: Ozanimod Ozanimod | 1件: D10968
D10968
| 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 3件: 13 13, 96, 97 |
581 | Ozonated olive oil | 2件: Olea europaea leaf Olea europaea leaf, Olive oil | 1件: D03311
D03311
| - | - | 2件: 35 35, 162 |
582 | Ozone | 1件: Ozone Ozone | - | - | - | 3件: 49 49, 51, 226 |
583 | Ozoralizumab | 1件: Ozoralizumab Ozoralizumab | 1件: D09944
D09944
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |